Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has announced a new board member- Dr Yasuhiro Suzuki. nnDr Suzuki has been appointed to the Board where he will sit as a representative of the CEPI Investors Council. This appointment was made following an election by CEPI’s investors’ representatives. He will replace Dr Ichiro Kurane whose term as Investor Board member has concluded. nnDr Suzuki served as Vice-Minister for Health and Chief Medical and Global Health Officer for the Government of Japan’s Ministry of Health, Labour and Welfare. He served as Executive Director for Social Change & Mental Health and Executive Director of Health Technology and Pharmaceuticals at the World Health Organisation (WHO). His expertise covers infectious diseases, mental health, environmental health, and health research policy.
SK bioscience has signed a new collaboration agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger ribonucleic acid (mRNA) vaccines for infectious diseases.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
OSLO, Norway and BILTHOVEN, Netherlands, Oct. 6, 2022 /PRNewswire/ -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI's US$200m program to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses.
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of...
CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax Inc. have announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.
OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. (Affinivax) today announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.
SEOUL, Oct. 6 (Yonhap) -- South Korean drugmaker SK Bioscience Co. said Wednesday it has signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to extend capacity reservations for manufacturing COVID-19 vaccines by the end of 2022.
EMERYVILLE, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of Gritstone’s CORAL COVID-19 vaccine program with an initial focus in South Africa.